Treatment of psoriatic skin lesions with a new Er:Yag laser technology: A case series study
Authors: Mohammad Jafferany
Diana S Urakova
Torello Lotti
Natalia G Kalashnikova
Journal: Dermatologic Therapy (2020)
Discipline: CLINICAL MEDICINE
Keywords: Er:YAG; PASI index; RecoSMA technology; laser; mechanical-acoustic effect
Affiliations: Department of Dermatology Linline Clinic Chain  Moscow Russia, Dermatology and Venereology Guglielmo Marconi University  Rome Italy, Department of Dermatology Institute of Medical and Social Technologies  Moscow Russia, College of Medicine Central Michigan University  Saginaw Michigan

Abstract:  Erbium: YAG (Er:YAG) laser with RecoSMA technology. This laser emits thousands of microbeams of energy causing superficial epidermal ablation and a separation of dermal fibers due to a mechanical-acoustic and resonance effect. The aim of this study is to evaluate the clinical efficacy of Erbium: YAG (Er:YAG) laser with RecoSMA in the treatment of stable psoriasis vulgaris lesions. A questionnaire completed by 112 patients enrolled in the study. Photographs taken before each session, the analysis of the dynamics index PASI and histological studies were analyzed to visually monitor the clinical progress. The analyses were carried out with the help of computer software. The results after treatment of average number of sessions per course showed the complete clinical remission of the skin lesions in over 87% of the patients treated. The Er:YAG laser and RecoSMA have demonstrated the high effectiveness of the laser method of treating skin manifestations of the disease and improving the quality of life of patients. 

Retracted: No

PubPeer comments:
 This paper does not appear to contain a conflict of interest statement, despite the first author seeming to be employed by the manufacturer (or an affiliate) of the device used [Linline Medical Systems] . The journal policy states: u201d**Conflict of Interest**. The journal requires that all authors disclose any potential sources of conflict of interest. Any interest or relationship, financial or otherwise that might be perceived as influencing an author s objectivity is considered a potential source of conflict of interest. These must be disclosed when directly relevant or directly related to the work that the authors describe in their manuscript. Potential sources of conflict of interest include, but are not limited to: patent or stock ownership, membership of a company board of directors, membership of an advisory board or committee for a company, and consultancy for or receipt of speaker s fees from a company. The existence of a conflict of interest does not preclude publication. If the authors have no conflict of interest to declare, they must also state this at submission. It is the responsibility of the corresponding author to review this policy with all authors and collectively to disclose with the submission ALL pertinent commercial and other relationships. https: onlinelibrary.wiley.com page journal 15298019 homepage forauthors.html#editorial I also did not locate a statement about funding, which also seems to be required by the journal. u201d**Funding**. Authors should list all funding sources in the Acknowledgments section. Authors are responsible for the accuracy of their funder designation. If in doubt, please check the Open Funder Registry for the correct nomenclature: https: www.crossref.org services funder-registry Apologies if I missed these disclosures. Note that the corresponding and last author listed a non-institutional email address in the paper, but I took the liberty of using his institutional address for the PP notification. , 
 #1 The last author s name seems familiar. ![] ,